Skip to main content
xMedica

NCT07919678ClinicalTrials.gov

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…

Phase 3656 participants sought40 sites2 countries

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 3 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.

How this score is built
  • Enrolment28/40

    656 participants (target)

  • Site count19/25

    40 sites

  • Country count7/15

    2 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    Pfizer has led 630 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.

Conditions

  • Obesity
  • Overweight
  • Osteoarthritis of the Knee

Eligibility

Eligibility
SexAll
Ages18 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Adults 18 years of age or older, or the minimum age of consent according to local regulations. * Body mass index of at least 27 kg/m² at Screening. * Currently meets American College of Rheumatology (ACR) Criteria for knee OA. * Pain due to knee OA. * Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3. * Willingness to complete the required analgesic washout. * History of at least 1 self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria * Self-reported body weight increase or decrease greater than 5% within 90 days before Screening. * History of diabetes or Screening laboratory findings indicative of diabetes. * Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease. * Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. * Significant active or unstable psychiatric disorder. * Condition or knee disorder that could confound assessment of target-knee pain. * Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study. * Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment. * Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo. * Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingQUADRUPLE (4)
Enrolment656 participants sought

Sponsor and collaborators

  • Pfizer Sponsor

Arms and interventions

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive placebo as subcutaneous injection

  • Arm 1: Berobenatide Once MonthlyEXPERIMENTAL

    Participants will receive berobenatide by subcutaneous injection.

  • Arm 2: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

  • Arm 3: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

Interventions

  • Drug Berobenatide

    Subcutaneous Injection

  • Other Placebo

    Subcutaneous Injection

Outcome measures

  1. Primary outcome

    Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score

    Time frame Baseline and Week 52

  2. Secondary outcome

    Percent change from baseline in Body Weight

    Time frame Baseline and Week 52

  3. Secondary outcome

    Change From Baseline in High-Sensitivity C-Reactive Protein

    Time frame Baseline and Week 52

  4. Secondary outcome

    Change from baseline in WOMAC Physical Function Subscale score

    Time frame Baseline and Week 52

  5. Secondary outcome

    Percentage of participants with ≥50% reduction in the WOMAC pain subscale score

    Time frame Baseline and Week 52

  6. Secondary outcome

    Percentage of participants with ≥30% reduction in the WOMAC pain subscale score

    Time frame Baseline and Week 52

  7. Secondary outcome

    Proportion of participants with utilization of protocol specified pain medication during the washout period

    Time frame Baseline and Week 52

  8. Secondary outcome

    Amount of protocol specified pain medication during the washout period

    Time frame Baseline and Week 52

  9. Secondary outcome

    Change from baseline in WOMAC stiffness score

    Time frame Baseline and Week 52

  10. Secondary outcome

    Change from baseline in WOMAC total score

    Time frame Baseline and Week 52

  11. Secondary outcome

    Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score

    Time frame Baseline and Week 52

  12. Secondary outcome

    Proportion of participants meeting OMERACT-OARSI

    Time frame Baseline and Week 52

  13. Secondary outcome

    Change from baseline in Average Pain Intensity-Numerical Rating Score

    Time frame Baseline and Week 52

  14. Secondary outcome

    Change from baseline in Worst Pain Intensity -Numerical Rating Score

    Time frame Baseline and Week 52

  15. Secondary outcome

    Change from baseline in SF-36 domain scales and component summary scales

    Time frame Baseline and Week 52

  16. Secondary outcome

    Change from baseline in Body Weight

    Time frame Baseline and Week 52

  17. Secondary outcome

    Change from Baseline in Body Mass Index

    Time frame Baseline and Week 52

  18. Secondary outcome

    Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame Baseline and Week 52

  19. Secondary outcome

    Number of Participants with Serious Adverse Events (SAE)

    Time frame Baseline and Week 52

  20. Secondary outcome

    Number of Participants with AE leading to permanent discontinuation from study intervention or study

    Time frame Baseline and Week 52

  21. Secondary outcome

    Number of Participants with Adverse Events of Special Interest (AESI)

    Time frame Baseline and Week 52

  22. Secondary outcome

    Number of Participants with Clinical laboratory abnormalities

    Time frame Baseline and Week 52

  23. Secondary outcome

    Change from baseline in timed walking distance at Week 52

    Time frame Baseline and Week 52

  24. Secondary outcome

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function

    Time frame Baseline and Week 52

  25. Secondary outcome

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain

    Time frame Baseline and Week 52

  26. Secondary outcome

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function

    Time frame Baseline and Week 52

  27. Secondary outcome

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain

    Time frame Baseline and Week 52

  28. Secondary outcome

    Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score

    Time frame Baseline and Week 52

  29. Secondary outcome

    Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score

    Time frame Baseline and Week 52

  30. Secondary outcome

    Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score

    Time frame Baseline and Week 52

  31. Secondary outcome

    Change From Baseline in WPAI:GH Work productivity loss score

    Time frame Baseline and Week 52

  32. Secondary outcome

    Change From Baseline in WPAI:GH Activity impairment score

    Time frame Baseline and Week 52

  33. Secondary outcome

    Change From Baseline in Systolic Blood Pressure (SBP)

    Time frame Baseline and Week 52

  34. Secondary outcome

    Change From Baseline in Diastolic Blood Pressure (DBP)

    Time frame Baseline and Week 52

  35. Secondary outcome

    Change From Baseline in Total Cholesterol

    Time frame Baseline and Week 52

  36. Secondary outcome

    Change From Baseline in High-density lipoprotein cholesterol (HDL-C)

    Time frame Baseline and Week 52

  37. Secondary outcome

    Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)

    Time frame Baseline and Week 52

  38. Secondary outcome

    Change from baseline in Non-HDL Cholesterol

    Time frame Baseline and Week 52

  39. Secondary outcome

    Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol

    Time frame Baseline and Week 52

  40. Secondary outcome

    Change from baseline in Triglycerides

    Time frame Baseline and Week 52

Dates

Dates
Start dateOctober 26, 2026 (actual)
Primary completionAugust 22, 2028 (estimated)
CompletionOctober 10, 2028 (estimated)
First postedNovember 5, 2026 (actual)
Last updatedNovember 5, 2026
Results postedNot stated in the registry record
Status last verifiedOctober 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

7 sites are recruiting

Canada

Canada
FacilityCityState or regionStatus
Bluewater Clinical Research Group Inc.SarniaOntarioNot yet recruiting

United States

United States
FacilityCityState or regionStatus
Albuquerque Clinical Trials, Inc.AlbuquerqueNew MexicoNot yet recruiting
Charlottesville Medical Research Center, LLCCharlottesvilleVirginiaNot yet recruiting
Northwestern University Feinberg School Of MedicineChicagoIllinoisNot yet recruiting
Great Lakes Clinical Trials, LLC dba Flourish ResearchChicagoIllinoisNot yet recruiting
Northwestern MedicineChicagoIllinoisNot yet recruiting
Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG)ChicagoIllinoisNot yet recruiting
Northwestern Memorial Hospital, Investigational Drug ServiceChicagoIllinoisNot yet recruiting
Clinical Research of West Florida, Inc.ClearwaterFloridaNot yet recruiting
Skylight Health ResearchColorado SpringsColoradoNot yet recruiting
Mercy Family ClinicDallasTexasNot yet recruiting
Universal Axon Clinical Research LLCDoralFloridaRecruiting
Altoona Center For Clinical ResearchDuncansvillePennsylvaniaRecruiting
Headlands Research California, LLCEscondidoCaliforniaNot yet recruiting
Profound Research LLCFarmington HillsMichiganRecruiting
Cedar Health ResearchFort WorthTexasNot yet recruiting
Novant Health Granite Quarry Internal Medicine (knee x-ray)Granite QuarryNorth CarolinaNot yet recruiting
BRCR Global LouisianaGretnaLouisianaNot yet recruiting
JCCT-JUNO NW HoustonHoustonTexasNot yet recruiting
Westside Center for Clinical ResearchJacksonvilleFloridaNot yet recruiting
Activian Clinical ResearchKingwoodTexasNot yet recruiting
Renstar Medical ResearchLady LakeFloridaNot yet recruiting
Monroe Biomedical ResearchMonroeNorth CarolinaRecruiting
AMR ClinicalNormanOklahomaNot yet recruiting
Renstar Medical ResearchOcalaFloridaNot yet recruiting
Prospective Research Innovations Inc.Rancho CucamongaCaliforniaNot yet recruiting
Accellacare - SalisburySalisburyNorth CarolinaNot yet recruiting
Consano Clinical Research, LLCShavano ParkTexasNot yet recruiting
Revive Research Institute, Inc.Sterling HeightsMichiganRecruiting
Clinical Research AtlantaStockbridgeGeorgiaNot yet recruiting
Clinical Research of West Florida, Inc.TampaFloridaNot yet recruiting
AMR ClinicalTempeArizonaNot yet recruiting
DM Clinical ResearchTomballTexasNot yet recruiting
Solace Clinical ResearchTustinCaliforniaNot yet recruiting
Velocity Clinical Research, WacoWacoTexasNot yet recruiting
Elevate Clinical ResearchWichitaKansasNot yet recruiting
Delaney RadiologistWilmingtonNorth CarolinaRecruiting
AccellacareWilmingtonNorth CarolinaRecruiting
North Georgia Internal MedicineWoodstockGeorgiaNot yet recruiting
North Georgia Clinical Research, LLCWoodstockGeorgiaNot yet recruiting

Study documents

No documents are linked in this registry record.

Changes over time

No changes have been recorded since we first ingested this record.

A change is recorded each time the sponsor updates the registry record. Status, dates, enrolment and sites appear here as they move.